Tech Company Financing Transactions
BreezeBio Funding Round
DSC Investment, Yuanta Asia Investment and ACVC Partners participated in a Series B venture round for BreezeBio. The round was recorded on 2/26/2026.
Transaction Overview
Company Name
Announced On
2/26/2026
Transaction Type
Venture Equity
Amount
Unknown
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to expand its platform with ligands conjugated to the nanoparticles for additional tissue and cell specificity, including delivery to T cells to enable in vivo CAR-T therapeutic development.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3000 Marina Blvd
Brisbane, CA 94005
USA
Brisbane, CA 94005
USA
Phone
Undisclosed
Website
Email Address
Overview
BreezeBio is a biotechnology company developing precision genetic medicines enabled by targeted, non-viral delivery across biologically relevant tissues. Using our proprietary NanoGalaxy® platform, we engineer nanoparticles designed to deliver genetic payloads, including mRNA, to specific cell types. Our platform has demonstrated delivery to immune cells as well as select tissues in the heart, lung, and central nervous system. We are advancing an internal therapeutic pipeline focused on autoimmune diseases and oncology. Our lead program, BRZ-101, is designed to restore immune tolerance in type 1 diabetes and is advancing into IND-enabling studies.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 2/26/2026: UpGuard venture capital transaction
Next: 2/27/2026: BrainCheck venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions on this site are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs








